Table 3

Distribution of process and outcome measures among adults with diabetes with comorbidities

Measure, n (%)Diabetes with comorbid hypertension n=273 592Diabetes with comorbid hypertension and chronic ischaemic heart disease n=141 947Diabetes with comorbid osteoarthritis
n=255 214
Diabetes with comorbid osteoarthritis and major depression n=2444
Process measures, n (%)
Having one or two HbA1c tests per year124 336 (45.4)61 505 (43.3)114 746 (45.0)964 (39.4)
Having three or more HbA1c tests per year77 942 (28.5)42 194 (29.7)72 469 (28.4)669 (27.9)
Annual eye examination177 080 (64.7)92 623 (65.3)171 803 (67.3)1386 (56.7)
Use of oral hypoglycaemic drugs148 344 (54.2)72 686 (51.2)130 599 (51.2)1102 (45.1)
Use of ACE inhibitors110 641 (40.4)69 296 (48.8)
Use of ARBs62 169 (22.7)32 997 (23.3)
Use of antiplatelet drugs34 868 (24.6)
Use of statins12 845 (79.5)
Use of NSAIDs – ‘negative’52 952 (20.8)452 (18.5)
Use of tetracyclic antidepressants – ‘negative’348 (14.2)
Use of benzodiazepines – ‘negative’860 (35.2)
Use of gaba receptor agonist – ‘negative’<6 (0.2)
Use of MAOIs – negative’9 (0.4)
Continuity of care index*
 Mean, (SD)0.59 (0.28)0.51 (0.27)0.55 (0.26)0.42 (0.26)
 Median (IQR)0.57 (0.36–0.82)0.49 (0.29–0.73)0.53 (0.32–0.77)0.36 (0.21–0.59)
Outcome measure, n (%)
All-cause hospitalisations45 520 (15.6)35 157 (24.8)49 873 (19.5)536 (29.0)
  • *Calculated using the Bice index.

  • ARBs, angiotensin II receptor blockers; HbA1c, glycated haemoglobin; MAOIs, monoamine oxidase inhibitors; NSAID, non-steroidal anti-inflammatory drugs.